Review of investigational drugs for coronavirus disease 2019

Dhruva Sharma, Neha Sharma, Preksha Sharma, Ganapathy Subramaniam

Abstract:
In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became evident in Wuhan, China, and then spread rapidly worldwide. Numerous drugs and vaccines are under clinical trial pipeline for investigation against coronavirus disease 2019 (COVID-19) infection. The aim of this systematic review was to discuss about investigational new as well as repurposed drugs currently under trial for COVID-19 infection. An exhaustive search was carried out for this review article including scientific databases of PubMed, Embase, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Web of Science, ScienceDirect, ProQuest, Google Scholar, and Scopus search engines using keywords of “Coronavirus,” “COVID-19,” “MERS-CoV,” “MERS,” “SARS-CoV-2,” and “SARS-CoV-1” and “Solidarity trial” and their Persian-equivalent keywords from inception until May 2020. After screening the 296 articles searched from different databases (PubMed = 97 and other search engines = 199), 52 articles were included in the final systematic review. It was found that the World Health Organization introduced a Solidarity international clinical trial to discover an effectual treatment of COVID-19. Based on established in vitro and in vivo activity against different strains of coronaviruses, four repurposed drugs – remdesivir, lopinavir/ritonavir combination, lopinavir/ritonavir with beta-1a, chloroquine, and hydroxychloroquine – were considered for clinical trial against COVID-19. A number of other drugs and vaccines are under clinical trial pipeline for investigation against COVID-19 infection. Despite multitude of treatment options available, treatment of choice is still not well established. Moreover, optimum supportive care and monitoring of seriously ill patients is the need of the hour.

Keywords: Coronavirus, coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, Solidarity trial

Introduction
In December 2019, the SARS-CoV-2 virus became evident in Wuhan, China, and then spread rapidly worldwide. Till date, three major epidemics of respiratory distress syndrome have been caused by three strains of coronaviruses (CoVs). In 2003, the severe acute respiratory syndrome coronavirus (SARS-CoV) was the first epidemic that was caused by coronavirus with epicenter in Guangdong, China. Middle East respiratory syndrome coronavirus (MERS-CoV) was the second epidemic that emerged in 2012 in Saudi Arabia, and recently, the 2019-novel coronavirus (2019-nCoV) or coronavirus disease 2019 (COVID-19) has occurred as the third epidemic of respiratory coronavirus which was mainly centered in Wuhan province, China. The novel virus was first isolated on January 7, 2020, and named as “2019-nCoV/SARS-CoV-2.” On March 11, 2020, COVID-19 was...
declared as coronavirus pandemic by the World Health Organization (WHO). Coronavirus-infected patients may remain asymptomatic, or they may experience mild-to-severe clinical symptoms such as pneumonia, respiratory failure, and ultimately death. The aim of this review was to discuss about investigational new as well as repurposed drugs currently under trial for COVID-19 infection.

Materials and Methods
A systematic search of literature evaluating treatment options available for coronavirus was performed by the investigators. The databases of PubMed, Embase, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Web of Science, ScienceDirect, ProQuest, Google Scholar, and Scopus search engines were systematically explored using the search terms “Coronavirus,” “COVID-19,” “MERS-CoV,” “SARS-CoV-2,” and “SARS-CoV-1,” “Prophylaxis,” and “Preventive” and “Solidarity trial” from inception until May 2020. Various alterations in spelling and abbreviations were applied due to the pronounced heterogeneity of this research field.

The titles and the abstracts of the relevant studies in English were procured using the search strategy, and they were independently screened by 3 authors, who eventually recaptured abstracts and the full text of articles to clinch the propriety. Dissent perseverance was executed by the fourth author. As the current pandemic is an extant public health dilemma, the systematic review protocol could not be preregistered. No presumptions or elucidation were contrived during the course of review.

Inclusion criteria were the insertion of the searched keywords in the title section and keywords of the articles. Studies in English only that possessed the information of investigational drugs for the treatment of COVID-19 infection (lopinavir/ritonavir, darunavir, ribavirin, remdesivir, favipiravir, oseltamivir, interferon-alpha [IFN-α], Arbidol, chloroquine phosphate, hydroxychloroquine, camostat mesylate, tocilizumab, sarilizumab, gimsilumab, azithromycin, baricitinib, ruxolitinib, tofacitinib, convalescent plasma [CP], and anticoagulation) were included. This included randomized controlled trials (RCTs) and observational studies (including cohort and control studies) along with the case reports (lopinavir/ritonavir, darunavir, ribavirin, remdesivir, favipiravir, oseltamivir, IFN-α, Arbidol, chloroquine phosphate, hydroxychloroquine, camostat mesylate, tocilizumab, sarilizumab, gimsilumab, azithromycin, baricitinib, ruxolitinib, tofacitinib, CP, and anticoagulation).

We excluded studies in other languages other than English and when no translation was available. Duplicate studies were also excluded from the search. The literature search was in accordance with PRISMA guidelines.

Results and Discussion
After preliminary screening of the databases, we could find 296 articles (PubMed = 97 and other search engines = 199). Further screening of title and abstract resulted in the exclusion of 120 duplicate articles. Full-text screening of the remaining 176 articles was done after the removal of duplicate records. Finally, 52 articles were included in the final systematic review. A flowchart demonstrating the search is presented in Figure 1.

Benefits in reducing mortality and viral load and time to clinical recovery were the primary outcome measures. The time required for negative seroconversion, length of hospital stay, overall survival, and adverse events were secondary outcome measures that were looked for while searching for investigational drugs.

It was found that the WHO introduced a Solidarity international clinical trial to discover an effectual treatment of COVID-19.

“Solidarity” clinical trial
The WHO introduced a Solidarity international clinical trial to discover an effectual treatment of COVID-19.
Extensive process of clinical trial will be curbed by 80% with the help of Solidarity trial. Almost 100 countries have participated in Solidarity trial by April 21, 2020. Based on established in vitro and in vivo activity against different strains of CoVs, four repurposed drugs – remdesivir, lopinavir/ritonavir combination, lopinavir/ritonavir with beta-1a, chloroquine, and hydroxychloroquine – were considered for clinical trial against COVID-19. Anyone of the above drugs is tested against local standard care of treatment.[6]

Considerable novel and repurposed pharmacotherapeutic agents against SARS-CoV-2 are under trial, but still, the specific drug treatment is the need of the hour.[7]

Drugs that are reported to be investigated for COVID-19 infection till date are depicted in Table 1.[7-9]

**Repurposed drugs investigated under Solidarity trial**

**Remdesivir**
Remdesivir is a broad-spectrum antiviral investigational drug.[10] Remdesivir is an adenosine analog and has been emerged as a promising antiviral drug against SARS/MERS-CoV. It gets incorporated into nascent viral RNA chains and causes its premature termination. Remdesivir was found to inhibit virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.[11]

In in vitro studies, it has shown inhibition of replication of both SARS-CoV and MERS-CoV.[12,13]

However, when remdesivir was combined with IFN-β, the results shown were superior to lopinavir, ritonavir, and IFN-β both in vitro and in a MERS-CoV mouse model.[14]

Remdesivir is a nucleotide analog that acts by inhibiting RNA polymerase enzyme. In a study on compassionate use of remdesivir among patients with COVID-19, the drug was administered in a dose of 200 mg intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. The study reported clinical improvement in 36 of 53 patients (68%).[15]

Recently, remdesivir has been approved for emergency use in COVID-19 infection.[16]

**Lopinavir with ritonavir booster**
Lopinavir is an antiretroviral drug which acts by inhibiting protease enzyme. It is used with ritonavir which is also a cytochrome enzyme inhibitor that increases the half-life of ritonavir.[17]

It was documented in a randomized open-labeled trial that a combination of lopinavir with ritonavir booster treatment added to standard supportive care among the SARS-CoV-2-infected patients, but it was not associated with clinical improvement or mortality in seriously ill

**Table 1: Depicting investigational pharmacotherapeutic agents for treatment of COVID-19 infection**

| Pharmacological class of drug | Name of drug | Mechanism of action |
|------------------------------|--------------|---------------------|
| Antiviral drugs              | Lopinavir/ritonavir | Inhibits 3-chymotrypsin-like protease |
|                              | Darunavir     | Inhibits 3-chymotrypsin-like protease |
|                              | Ribavirin     | RNA dependent         |
|                              | Remdesivir    | RNA dependent         |
|                              | Favipiravir   | RNA dependent         |
| Neuraminidase inhibitor      | Oseltamivir   | Inhibits influenza A and B virus neuraminidase |
| Interferons                  | IFN-α         | Interferes with viral replication |
| Broad-spectrum antiviral     | Arbidol       | Targets S protein/ACE2 interaction |
| Antimalarial drug            | Chloroquine phosphate | Inhibits viral release into intracellular space, upregulate cell surface ACE-2, reduce glycosylation of ACE-2 |
| Hydroxychloroquine           | Camostat mesylate | Type 2 transmembrane serine protease |
| Serine protease inhibitor    | Tocilizumab   | Binds IL-6 receptor |
| IL-6 receptor antagonist     | Sarilizumab   | Prevenets IL-6 receptor activation, Inhibits IL-6 signaling |
| GM- CSF inhibitor            | Gimsilumab    | Acts against GM-CSF |

RNA=Ribonucleic acid, ACE=Angiotensin-converting enzyme 2, GM-CSF=Granulocyte-macrophage colony-stimulating factor
patients with COVID-19 different from that associated with standard care alone.\textsuperscript{18,19}

**Interferons**

It has been noted in the previously published literature that IFN-I treatment has activity against MERS-CoV and SARS-CoV.\textsuperscript{20} It has been investigated in numerous experiments both \textit{in vitro} and \textit{in vivo}.\textsuperscript{14}

The IFNβ subtype appears to be the most suited for early stages of COVID-19 treatment.\textsuperscript{21}

**Chloroquine and hydroxychloroquine**

Chloroquine, which is used as an antimalarial drug, has recently been documented as a potential broad-spectrum antiviral drug. It increases viral endosomal pH and also interferes with the glycosylation of cellular receptors of SARS-CoV.

In Vero E6 cells, chloroquine was found to have action at both entry and at postentry stages of the 2019-nCoV infection.\textsuperscript{22,23}

The multimodal action of chloroquine in inhibition of coronavirus is illustrated in Figure 2.

It has been documented in a study that hydroxychloroquine treatment was significantly associated with reduction/disappearance of viral load in COVID-19 patients. This effect was augmented by the addition of azithromycin. In this study, patients were randomized to receive 600 mg of hydroxychloroquine daily, and their viral load in nasopharyngeal swabs was tested daily in a hospital setting.\textsuperscript{24}

Another Chinese study recommended treatment of patients diagnosed as mild, moderate, and severe cases of COVID-19 pneumonia and without contraindications to chloroquine, with 500 mg chloroquine twice a day for 10 days.\textsuperscript{25}

Hydroxychloroquine has a better clinical safety profile than that of chloroquine (during long-term use). Thus, it can be tolerated in higher daily dose with less concerns of drug–drug interactions.\textsuperscript{26}

Data from \textit{in vitro} and \textit{in vivo} studies are limited, with mixed results and confounded with bias. Chloroquine is known to cause prolonged QT syndrome and torsade de pointes. Other drugs causing cardiovascular side effects are shown in Table 2.

**Other drugs under investigation for COVID-19 infection**

**Ribavirin**

Ribavirin is a guanosine analog and acts against both RNA and DNA viruses. It acts by multiple mechanisms. It interferes with the functioning of polymerase enzyme. It also causes the destabilization of viral RNA and also inhibits inosine monophosphate dehydrogenase and thereby inhibits the formation of guanosine.\textsuperscript{31}

It has shown its efficacy in SARS-CoV and MERS-CoV epidemic. Initially, it was given in a dose of 4-g oral loading dose followed by a 1.2-g oral dose every 8 h.\textsuperscript{32-34} The dose was then modified to 500 mg IV BID or TID.

Low cost of ribavirin and its efficacy to treat COVID infection justify its use in clinical trials.\textsuperscript{35}

**Favipiravir**

Favipiravir has been shown its efficacy in the treatment of influenza, and Ebola virus is basically a prodrug and acts by inhibiting RNA-dependent RNA polymerase inhibitor.\textsuperscript{36,37}

Favipiravir has shown its antiviral efficacy against SARS infection in \textit{in vitro} studies.\textsuperscript{1,36}

In an open-labeled trial, favipiravir was given orally in a dose of 1600 mg twice daily on day 1 and 600 mg twice daily on days 2–14. It was compared against lopinavir/ritonavir, while IFN-α was administered to

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|}
\hline
Pharmacologic class of drug & Name of drug & Cardiovascular side effect \\
\hline
Antimalarial\textsuperscript{27-28} & Chloroquine & Prolongation of QT interval, arrhythmias in seriously ill patients, torsade de pointes \\
\hline
Antimalarial\textsuperscript{27-28} & Hydroxychloroquine & Prolongation of QT interval, arrhythmias in seriously ill patients, torsade de pointes \\
\hline
Protease inhibitor\textsuperscript{27-28} & Lopinavir; ritonavir & QT prolongation, torsade de pointes \\
\hline
Macrolide\textsuperscript{27-28} & Azithromycin & QT prolongation, torsade de pointes \\
\hline
Janus kinase inhibitors\textsuperscript{29-30} & Baricitinib, ruxolitinib, tofacitinib & DVT and PE \\
\hline
\end{tabular}
\end{table}

DVT=Deep vein thrombosis, PE=Pulmonary embolism
all participants. A shorter viral clearance time was found with significant improvement in chest imaging which was observed. Favipiravir showed better therapeutic responses on COVID-19 in terms of disease progression and viral clearance.[38]

**Monoclonal antibody Tocilizumab**

Tocilizumab is a humanized monoclonal antibody which acts against the interleukin-6 receptor. It was suggested in recent literature that IL-6 is one of the most crucial cytokines which was documented to be involved in COVID-19-induced cytokine storms. Thus, tocilizumab emerged as one of the treatment strategies among COVID-19-infected patients. Luo *et al.* implied the effectiveness of tocilizumab treatment in COVID-19 patients with a risk of cytokine storms and emphasized that the dose of tocilizumab can be repeated among critically ill patients with elevated IL-6.[39,40]

**Gimsilumab**

Gimsilumab is a fully human monoclonal antibody. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is documented to be involved in hyperinflammation of the lung and increase in pro-inflammatory cytokines and chemokines. Gimsilumab is thought to act on these GM-CSFs.[41]

**Recombinant human angiotensin-converting enzyme 2**

It was confirmed in an *in vitro* study that angiotensin-converting enzyme 2 (ACE2) expression corroborates with susceptibility to SARS-CoV infection. Hence, it was assumed that higher ACE2 expression might also lead to a higher risk of SARS-CoV-2 infection.[42]

In COVID-19 patients, coronary artery disease and hypertension are considered as remarkable mortality.[43]

Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in addition to their main pharmacological effect to inhibit ACE1 or block angiotensin II type 1 receptor, they are able to upregulate ACE2 expression and render the patient susceptible to the infection of SARS-CoV-2.

Therefore, it was suggested that ACEIs and ARBs should be avoided in COVID infection.[44] Moreover, it has been documented in recent findings that serum level of angiotensin II is significantly elevated in COVID-19 patients and it shows a linear positive correlation to viral load and lung injury.[45]

Thus, there are mixed recommendations for ACEI and ARB, whether to continue or discontinue. Despite these, it has been suggested not to discontinue these drugs to prevent potential lung and heart injury, although exogenous supplement of rhACE2 may be a potential way to prevent and treat COVID-19.

Potential nCoV-RBD-hACE2 interaction-blocking peptides were designed that may restrict viral attachment and entry. Experimental validation is needed for these peptides need to test their therapeutic efficacy.[46]

**Azithromycin**

Viral load reduction in COVID-19 patients was found to be significantly associated with hydroxychloroquine treatment which was further reinforced by the addition of azithromycin. However, its use along with chloroquine might result in prolonged QT syndrome.[24]

**Convalescent plasma**

CP or immune plasma has materialized as one-fourth buoyant treatments for COVID-19 infection. Plasma that is collected from an infected individual which is then transfused into infected patients as a postexposure prophylaxis is termed as CP.[47,48]

Antibodies that are derived from CP are able to neutralize a virus by inhibition of its replication.[49]

The use of CP therapy among patients infected with COVID-19 was approved by FDA on March 24, 2020.[50]

**Corticosteroids and nonsteroidal anti-inflammatory drugs**

Regarding the use of corticosteroids and nonsteroidal anti-inflammatory drugs, mixed results have been documented as per the paramount knowledge of researchers. There is a dire need to exercise caution regarding the use of corticosteroids in COVID-19 patients until emergence of further evidence.[51]

**Anticoagulation**

It is becoming evident from the recent studies that disseminated intravascular coagulation can complicate severe coronavirus disease and these patients are at high risk of venous thromboembolism. D-dimer might prove to significantly important in predicting outcome among these patients.[52]

Expert consensus has recommended the application of heparin in seriously ill COVID-19 patients because they are at a high risk of disseminated intravascular coagulation and venous thromboembolism. Tang *et al.* emphasized the association of low-molecular-weight heparin with better prognosis in seriously ill COVID-19 patients meeting sepsis-induced coagulopathy criteria or with strikingly upraised D-dimer.[53,54]

The measurement of D-dimer and fibrinogen levels in screening of coagulation tests is suggested.[55]
Conclusion

Corona pandemic has brought a huge challenge to health-care system. Testing a new drug is itself a giant challenge in such a state of dire emergency. In spite of multitude treatment options available, there is still a dire need to search an ideal drug molecule with lesser side effects, which may improve the patient compliance. Moreover, optimum supportive care and monitoring of seriously ill patients is the need of the hour. The safe and effective management skills of health-care professionals in this unprecedented time of coronavirus infection are highly appreciated. Nonetheless, long-term data of RCTs of their investigational drugs should validate their efficacy and safety in the management of COVID-19 infection. The development of impressive vaccines to discontinue the spread of SARS-CoV-2 is the need of the hour.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References

1. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58-60.
2. Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmocol 2020;52:1-5.
3. Graham RL, Donaldson EF, Baric RS. A decade after SARS: Strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013;11:836-48.
4. World Health Organization. SARS (Severe Acute Respiratory Syndrome). World Health Organization. Available from: https://www.who.int/ith/diseases/sars/en/. [Last accessed on 2020 Apr 27].
5. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81.
6. World Health Organization.Org. Solidarity Clinical Trial for COVID-19 Treatments. Available from: http://www.who.int/diseases/novel-coronavirus-2019/solidarity-trial. [Last accessed on 2020 Apr 30].
7. Borges do Nascimento IJ, Cacic N, Abdulazeez HM, von Groote TC, Jayarajah U, Weerasekara, et al. Novel coronavirus infection (COVID-19) in humans: A scoping review and meta-analysis. J Clin Med 2020;9:941.
8. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: The mystery and the miracle. J Med Virol 2020;92:401-2.
9. Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. Drug targets for corona virus: A systematic review. Indian J Pharmocol 2020;52:56-65.
10. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020;34:101615.
11. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel...
coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
12. Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9 (2):e00221-18.
13. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;9 (396):eaal3653.
14. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.
15. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020;382:2327-36.
16. FDA. Remdesivir EUA Letter of Authorization FDA. Available from: http://www.fda.gov/media. [Last accessed on 2020 May 04].
17. Vie AB. Kaletra Prescribing Information; 2020. Available from: http://www.rxabbvie.com/pdf/kaletratabpi.pdf. [Last accessed on 2020 Apr 28].
18. Cao B, Yang W, Wen D, Liu W, et al. A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19. New Engl J Med. 2020;382:1787-1799.
19. Stower H. Lopinavir-ritonavir in severe Covid-19. Nat Med 2020;26:465.
20. Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med 2006;3:e343.
21. Sallarda E, Lescureb FX, Yazdanpanahb Y. Type 1 interferons and Remdesivir in the treatment of coronaviruses. Rev Med Virol 2006;16:37-48.
22. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet 2003;361:1767-72.
23. Lee N, Hui D, Wu A, Chan Pet al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94.
24. Osterreich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela CS. Günther successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014;105:17-21.
25. Madelain V, Osterreich L, Grav F, Nguyen TH, De Lamballerie X, Mentré F, et al. Ebola virus dynamics in mice treated with favipiravir. Antiviral Res 2015;123:70-7.
26. Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med 2006;3:e343.
27. Vie AB. Kaletra Prescribing Information; 2020. Available from: http://www.rxabbvie.com/pdf/kaletratabpi.pdf. [Last accessed on 2020 May 02].
28. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, et al. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 2004;319:1216-21.
29. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.
30. Liu Y, Cheng X, Zeng Q, Chen Z, Wang Z, Yuan J, et al. Expert recommendations for management and treatment of cardiovascular diseases under the epidemic situation of novel coronavirus pneumonia in Hubei province. J Clin Cardiol 2020;36:201-3.
31. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63:364-74.
32. Barh D, Tiwari S, Silva Andrade B, et al. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain. F1000Res. 2020;9:576.
33. Barb D, Tiwari S, Silva Andrade B, et al. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain. F1000Res. 2020;9:576.
34. Teixeira da Silva JA. Convalescent plasma: A possible treatment of COVID-19 in India. Med J Armed Forces India. 2020;76(2):236-237.
35. Bloch E.M., Shoham S., Casadevall A. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 doi: 10.1172/JCI138745. in press.
36. van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol 2020;10:548.
37. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020;368:m1256.
38. Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID‑19 and cardiovascular disease. Eur Heart J. 2020 Mar 18;41(12):923-5.
39. Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol 2020;92:740-6.
40. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, et al. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 2004;319:1216-21.
41. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.
42. Lia Y, Cheng X, Zeng Q, Chen Z, Wang Z, Yuan J, et al. Expert recommendations for management and treatment of cardiovascular diseases under the epidemic situation of novel coronavirus pneumonia in Hubei province. J Clin Cardiol 2020;36:201-3.
43. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63:364-74.
44. Barh D, Tiwari S, Silva Andrade B, et al. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain. F1000Res. 2020;9:576.
45. Bloch E.M., Shoham S., Casadevall A. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 doi: 10.1172/JCI138745. in press.
46. van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol 2020;10:548.
47. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020;368:m1256.
48. Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID‑19 and cardiovascular disease. Eur Heart J. 2020 Mar 18;41(12):923-5.
action. Br J Haematol. 2020;189 (5):846-847.

53. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094-9.

54. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 [published online ahead of print, 2020 Apr 3]. J Thromb Thrombolysis. 2020;1-4.

55. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135 (23):2033-2040.

56. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323 (18):1824-1836.

57. WHO. Bacille Calmette-Guérin. Vaccination and COVID-19. Available from: https://www.who.int/news-room/commentaries/detail/bacilli-calmette-guer-%C3%A9rin-(bcg)-vaccination-and-covid-19. [Last assessed on 2020 May 02].

58. Ministry of Health and Family Welfare. Government of India. COVID-19 INDIA. Available from: https://www.mohfw.gov.in/. [Last assessed 2020 May 03; Last accessed on 2020 Apr 30].

59. National Taskforce for COVID-19. Advisory on the use of Hydroxy-Chloroquine as Prophylaxis for SARS-CoV-2 Infection. Available from: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforsARSCoV2infection.pdf. [Last accessed on 2020 May 02].